MabGenesis, Inc.

MabGenesis, Inc.

TTSE:653A
666.00
JPY
+37.00
(+5.88%)
MabGenesis, Inc.
TSE:653A
(Tokyo Stock Exchange)

Recent

price

666.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
MabGenesis, Inc. operates as a biopharmaceutical company that develops therapeutic monoclonal antibody drugs in the human and animal fields. It develops antibody libraries as MOURA Libraries in terms of functionality and completeness, and highly efficient monoclonal antibody isolation technology. The company was founded on June. 3, 2019 and is headquartered in Yokohama, Japan.